Assay Prediction

Pathology

Clinical Features

Tissue of Origin

Veridex

Histology

IHC

Age/Sex

Sites of Metastasis

Intra-abdominal Location (Y/N)

Response to Treatment

Survival (mo)

Colorectal

Colon

Adenocarcinoma

CK20+, CK7-, TTF1-, CEA-

73/F

Pleura, left adrenal

Y

SD

23

Colorectal

Other

Adenocarcinoma

None

64/F

Liver, omentum, peritoneum, pancreas

Y

UE

1

Colorectal

Pancreas

Adenocarcinoma

CK7+, CK20-, CA125-, TTF1-, CEA-

66/F

Liver

Y

UE

4

Colorectal

NSCLC

PD adenocarcinoma

CK+, CK20+, PLAP-, PSA/PSAP-, melanin A-

71/M

Abdomen, Soft tissue

Y

SD

21

Pancreas

Colon

Adenocarcinoma

None

44/F

Liver, abdominal wall, peritoneum

Y

UE

1

Kidney

Colon

PD carcinoma

CK+, calretinin+, vimentin+, chromogranin-, CD15-, CD10-, AFP-, CEA-

64/M

Liver, peritoneum

Y

SD

6

NSCLC

Colon

Squamous

None

59/M

Lymph nodes, internal jugular vein mass

N

PD

7

 

 

 

 

 

 

 

 

 

Ovary

Ovary

PD carcinoma

CK7+, ER+, PR+, GCDFP15-, HER2-

69/F

Lung, liver, lymph nodes, pelvis, abdomen

Y

PR

57

Ovary

Ovary

PD carcinoma

AE1/AE3+, CK7+, EMA+, CK5/6+, calretinin+, pan keratin+, CEA-, CK20-, LeuM1-, thyroglobulin-, ER-, PR-, Her2/neu-, HMB45-, S100-,chromogranin-, synaptophysin-, NSE-

45/F

Lung, bone, pelvis, lymph nodes, mediastinum

Y

SD

6

Ovary

Other

Adenocarcinoma

CK7+, CD15+, CEA+, calretinin-, CK20-, GCDFP15-, S100-, TTF1-

70/F

Lung

N

PR

19

Ovary

Other

PD adenocarcinoma

None

48/F

Lung, liver, mediastinum

Y

SD

18

Ovary

NSCLC

PD adenocarcinoma

CK+, CK7+, CEA+, ER-, PR-, HER2-, CK20-, HMB45-, S100-

51/F

Lung, liver

Y

PD

5

Sarcoma

Ovary

PD carcinoma

vimentin+, NSE+, CD117+, synaptophysin+, S100-, HMB45-, LCA-, chromogranin-, actin-, desmin-, pan CK-, EMA-

40/F

Lung, liver, pelvis

Y

PD

9

Table 4: Clinicopathologic Characteristics of Patients with Colorectal (n = 7) or Ovary (n = 6) Prediction.